Novo Nordisk A/S (NVO) Q3 2024 Earnings Conference Call November 6, 2024 7:00 AM ET Company Participants Jacob Martin Wiborg Rode - Head of Investor Relations Lars Fruergaard Jorgensen - President and Chief Executive Officer Camilla Sylvest - Executive Vice President and Head of Commercial Strategy & Corporate Affairs Doug Langa - Executive Vice President and Head of North America Operations Martin Holst Lange - Executive Vice President and Head of Development Karsten Munk Knudsen - Executive Vice President ...

Key TakeawaysAfter rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of estimates despite continued growth form weight-loss drugs Ozempic and Wegovy.Sales rose 21% from the same time last year, but analysts had expected them to rise a bit higher.The Danish drugmaker also narrowed its full-year projections for revenue and operating profit. After rising in premarket trading, Novo Nordisk's (NVO) U.S.-listed shares fell a ...

Key TakeawaysNovo Nordisk's U.S.-listed shares rose Wednesday morning as third-quarter profits beat estimates and sales of Ozempic and Wegovy continued to grow.Sales rose 21% from the same time last year, but analysts had expected them to rise a bit higher.The Danish drugmaker also narrowed its full-year projections for revenue and operating profit. Novo Nordisk's (NVO) U.S.-listed shares rose Wednesday morning as it reported better third-quarter profits than expected, though sales of its drugs including po ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year growth guidance.The Danish pharmaceutical giant said that its net profit in the third quarter hit 27.3 billion Danish kroner ($3.92 billion), above an LSEG aggregate estimate of 26.95 billion Danish kroner.EBIT — earnings before tax and income — came to 33.8 billion Danish kroner, also just above the LSEG forecast of 33.51 billion Danish kroner.The company also narrowed its sales growt ...

Financial Performance - Operating profit increased by 21% in Danish kroner and by 22% at constant exchange rates (CER) to DKK 91.6 billion [1] - Net sales grew by 23% in Danish kroner (24% at CER) to DKK 204,720 million [2] - Net profit increased by 18% to DKK 72,758 million [2] - Diluted earnings per share grew by 19% to DKK 16.29 [2] Regional Sales Performance - North America Operations sales increased by 31% in Danish kroner (31% at CER) [1] - International Operations sales grew by 13% in Danish kroner (15% at CER) [1] Therapeutic Area Performance - Diabetes and Obesity care sales increased by 25% in Danish kroner (26% at CER) to DKK 191.8 billion [1] - GLP-1 diabetes sales grew by 25% in Danish kroner (26% at CER) [1] - Obesity care sales surged by 44% in Danish kroner (44% at CER) to DKK 43.7 billion [1] - Rare disease sales increased by 3% in both Danish kroner and at CER [1] R&D Progress - Completed phase 2a trial with monlunabant in obesity, with phase 2b trial planned for 2025 [1] - Oral semaglutide demonstrated statistically significant reduction in major adverse cardiovascular events in the SOUL trial [1] - Semaglutide 2.4 mg showed superior improvement in liver fibrosis and MASH resolution in the ESSENCE trial [1] 2024 Outlook - Sales growth expected to be 23-27% at CER [1] - Operating profit growth projected at 21-27% at CER [1] - Growth in Danish kroner expected to be 1 percentage point lower than CER for sales and 2 percentage points lower for operating profit [1] Company Overview - Global healthcare company founded in 1923, headquartered in Denmark [4] - Focuses on defeating serious chronic diseases, with heritage in diabetes [4] - Employs approximately 72,000 people in 80 countries [4] - Markets products in around 170 countries [4] - Listed on Nasdaq Copenhagen (Novo-B) and New York Stock Exchange (NVO) [4] Leadership Commentary - CEO highlighted strong performance driven by GLP-1-based diabetes and obesity treatments [3] - Emphasized positive R&D read-outs across semaglutide portfolio [3]

Key TakeawaysDanish pharmaceutical giant Novo Nordisk is set to report earnings for the third quarter of 2024 on Wednesday morning.Sales of its popular weight-loss drugs Ozempic and Wegovy will be Novo investors' focus.Analysts are generaly bullish on the stock, with five "hold" ratings and six "buy" ratings and an average price target about 28% above recent levels. Novo Nordisk (NVO), maker of popular weight-loss drugs Ozempic and Wegovy, is set to report third-quarter earnings Wednesday morning, with Wall ...

Core Insights - Novo Nordisk announced positive results from part 1 of the ESSENCE trial, demonstrating the efficacy of semaglutide 2.4 mg in treating metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis [1][2][3] Group 1: Trial Results - The ESSENCE trial achieved its primary endpoints, showing a statistically significant improvement in liver fibrosis and resolution of steatohepatitis with semaglutide 2.4 mg compared to placebo [2] - At week 72, 37.0% of participants treated with semaglutide showed improvement in liver fibrosis without worsening steatohepatitis, compared to 22.5% in the placebo group [2] - Additionally, 62.9% of those on semaglutide achieved resolution of steatohepatitis without worsening liver fibrosis, versus 34.1% on placebo [2] Group 2: Drug Profile and Market Potential - Semaglutide 2.4 mg is a GLP-1 receptor agonist marketed as Wegovy®, indicated for chronic weight management in adults with obesity or overweight [6][7] - The drug has a well-tolerated safety profile consistent with previous trials, indicating its potential for broader application in treating MASH [3] - Novo Nordisk plans to file for regulatory approvals in the US and EU in the first half of 2025, with detailed results to be presented at a scientific conference in 2024 [3] Group 3: Disease Context - MASH is a serious and progressive liver disease affecting over 250 million people globally, with the number of individuals in advanced stages expected to double by 2030 [4] - Among those who are overweight or obese, more than one in three are also living with MASH, highlighting a significant unmet medical need [4]

Weight loss syringes of the brands "Wegovy", "Ozempic" and "Mounjaro" are sold at In der Achat Apotheke in Mitte, Germany. All doses of Novo Nordisk's highly popular weight loss injection Wegovy and diabetes drug Ozempic are now available in the U.S., according to an update on the U.S. Food and Drug Administration's drug shortage database on Wednesday. It is a sign that Novo Nordisk's efforts to ramp up the supply of those weekly drugs are starting to pay off, as demand continues to skyrocket in the U.S. A ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

Novo Nordisk just released data from a clinical trial featuring its oral semaglutide treatment, Rybelsus.Danish pharmaceutical company Novo Nordisk (NVO -0.47%) is pioneering a new wave of medical treatment for diabetes and obesity care.The company develops a long line of blockbuster glucagon-like peptide-1 (GLP-1) agonists, including Ozempic, Wegovy, Rybelsus, and Saxenda. The main compound that Ozempic, Wegovy, and Rybelsus share is called semaglutide.However, what sets Rybelsus apart from its sibling tre ...